Does survivin overexpression enhance the efficiency of fibroblast cell-based wound therapy?

Molecular Biology Reports
Fereshteh Shojaei-GhahrizjaniMehdi Banitalebi-Dehkordi

Abstract

Cell-based wound therapy is faced with some limiting factors that decrease the therapeutic efficacy of transplanted cells. In this study, we aimed to genetically modify fibroblast cells with anti-apoptotic Survivin gene (Birc5) before cell transplantation. In vitro, pIRES2-eGFP-Survivin plasmid was transfected into the fibroblast cells and the growth curve was evaluated for transfected and normal cells performing MTT assay. In vivo, two 6-diameter cutaneous wounds were created at mice dorsal skin. Fibrin clot was used as a delivery vehicle to transfer cells into the wound bed. The effects of four treatment groups including (a) Cell-SVV-Clot (b) Cell-GFP-Clot, (c) Normal cell-Clot and, (d) Clot alone were evaluated. After 1,2,3,7 and 14 days post-transplantation, the wounds were photographed for evaluating the wound closure rate and wound samples were obtained. Angiogenesis and formation of granulated tissue were assessed via H&E staining for wound samples. The expression levels of Survivin, VEGF, and bFGF genes were also determined using qRT-PCR. The MTT assay showed similar proliferation potential of transfected cells with normal cells verifying that Survivin had no detrimental effect. Compared to the Normal cell-Clot group, t...Continue Reading

References

Apr 1, 1996·Biological & Pharmaceutical Bulletin·M OkumuraM Yajima
Jan 23, 1999·Plastic and Reconstructive Surgery·J ChangA E Turk
Oct 4, 2005·Journal of the American College of Cardiology·Yao Liang TangM Ian Phillips
Sep 12, 2006·Biomaterials·Daniela EyrichTorsten Blunk
Jan 18, 2007·Molecular Medicine·Tobias HirschLars Steinstraesser
Sep 7, 2007·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Nele KindtEdward M Conway
Dec 10, 2009·Journal of Tissue Viability·Bin Li, James H-C Wang
Feb 22, 2011·Surgical Oncology·Kumkum JhaManoj Pandey
Jan 1, 2008·CSH Protocols·Andrew H FischerRolf Zeller
Mar 4, 2011·Langenbeck's Archives of Surgery·Jörn Andreas LohmeyerHans-Günther Machens
May 13, 2011·Kidney International·Andrea Havasi, Steven C Borkan
Aug 21, 2013·Journal of the American Society of Nephrology : JASN·Jianchun ChenRaymond C Harris
Sep 23, 2014·Burns : Journal of the International Society for Burn Injuries·Anthony J P CloverNoel M Caplice
Apr 2, 2015·International Journal of Molecular Sciences·Eric Birkenhauer, Suresh Neethirajan
May 31, 2018·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·Fereshteh ShojaeiMilad Khorramian-Ghahfarokhi
Oct 27, 2018·Journal of Transplantation·Sara AssadiaslAliakbar Amirzargar
Dec 24, 2018·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Eric D MillerNaduparambil K Jacob
Feb 23, 2019·Biomaterials Science·Seyedeh Mehrnaz KouhbananinejadAlireza Farsinejad
May 31, 2019·Wound Repair and Regeneration : Official Publication of the Wound Healing Society [and] the European Tissue Repair Society·Yukie MoriHiromi Sanada

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
biopsy
PCR
genetic modification

Software Mentioned

Image J
Cell
SPSS
NIH ImageJ
Graphpad Prism

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.